Register entry
Stemline Therapeutics, Inc.
- Registered sites
- 1
- Drug products
- 3
- Live patents
- 14
- Countries
- 1
- Base
- Germany
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testing
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| A. Menarini Research & Business Service GmbH | BerlinGermany | Analytical testing | 3010666018 |
Exclusivity
Patents
14Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ORSERDU | ELACESTRANT HYDROCHLORIDE | Oct 2034 |
| ORSERDU | ELACESTRANT HYDROCHLORIDE | Oct 2036 |
| ORSERDU | ELACESTRANT HYDROCHLORIDE | Feb 2037 |
| ORSERDU | ELACESTRANT HYDROCHLORIDE | Jan 2038 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| Elzonris | tagraxofusp | INJECTION, SOLUTION | BLA |
| ORSERDU | Elacestrant | TABLET, FILM COATED | NDA |
| ORSERDU | Elacestrant | TABLET, FILM COATED | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.